NCT01439490

FES-PET to Determine ER-expression in Epithelial Ovarian Cancer

Feasibility Study: FES-PET to Determine ER-expression in Epithelial Ovarian Cancer

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 15 (actual)
• Sponsor: University Medical Center Groningen · Academic / Other
• Sex: Female
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Estrogens are implicated in the development of ovarian cancer and estrogen receptors (ER) alpha and beta are present in 20-100% of ovarian cancer patients. For this reason, antihormonal therapy with anti-estrogens or ER-antagonists is potentially an attractive treatment option. However, only a small proportion of patients (5-19%) will respond to antihormonal therapy. ER-expression in ER-positive breast cancer can be assessed by positron emission tomography (PET) with \[18F\]fluoroestradiol (FES). In this study the investigators will evaluate whether FES-PET can be used to visualize and quantify ER-expression in ovarian cancer. If these results are positive, this would warrant further exploration of FES-PET imaging in ovarian cancer.

Detailed description

Investigators will evaluate whether FES-PET can be used to visualize and quantify ER-expression in ovarian cancer. If these results are positive, this would warrant further exploration of FES-PET imaging in ovarian cancer.

Conditions

• Epithelial Ovarian Cancer

Interventions

Type	Name	Description
OTHER	FES-PET	Patients undergo FES-PET prior to obtaining histology

Timeline

• Start date: 2011-08-01
• Primary completion: 2014-02-01
• Completion: 2014-02-01
• First posted: 2011-09-23
• Last updated: 2024-05-06

Locations

1 site across 1 country: Netherlands